Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer
- 23 March 2012
- journal article
- research article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 13 (5), 391-395
- https://doi.org/10.1016/j.cllc.2012.01.003
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2011
- Treatment of Non–Small-Cell Lung Cancer with Erlotinib or GefitinibThe New England Journal of Medicine, 2011
- Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancerCancer Science, 2008
- Expression and mutational analysis of MET in human solid cancersGenes, Chromosomes and Cancer, 2008
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences of the United States of America, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Lung Cancer Cell Lines HarboringMETGene Amplification Are Dependent on Met for Growth and SurvivalCancer Research, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2006
- Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung CancerCancer Research, 2005